Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study
<strong>Background</strong> Bisphosphonates are contraindicated in patients with stage 4+ chronic kidney disease. However, they are widely used to prevent fragility fractures in stage 3 chronic kidney disease, despite a lack of good-quality data on their effects. <br> <strong>...
Հիմնական հեղինակներ: | Robinson, DE, Ali, MS, Strauss, VY, Elhussein, L, Abrahamsen, B, Arden, NK, Ben-Shlomo, Y, Caskey, F, Cooper, C, Dedman, D, Delmestri, A, Judge, A, Javaid, MK, Prieto-Alhambra, D |
---|---|
Ձևաչափ: | Journal article |
Լեզու: | English |
Հրապարակվել է: |
National Institute for Health Research
2021
|
Նմանատիպ նյութեր
-
Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study
: Robinson, DE, և այլն
Հրապարակվել է: (2021) -
Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study
: Danielle E Robinson, և այլն
Հրապարակվել է: (2021-03-01) -
Oral bisphosphonate use and risk of acute kidney injury, gastrointestinal events and hypocalcaemia in patients with moderate-advanced chronic kidney disease: a population-based cohort study
: Ali, MS, և այլն
Հրապարակվել է: (2017) -
Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis
: Robinson, DE, և այլն
Հրապարակվել է: (2021) -
Bisphosphonates and Age-Related Macular Degeneration: A Propensity-Matched Cohort and Nested Case-Control Analysis
: Garriga, C, և այլն
Հրապարակվել է: (2017)